08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Brovana: Phase III data

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary reported data from a double-blind, U.S. Phase III trial in 841 patients with moderate to severe COPD showing that twice-daily 15 µg Brovana met the primary endpoint of non-inferiority to...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Company News

Elevation Pharmaceuticals, Dainippon Sumitomo deal

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary will acquire Elevation for $100 million up front and up to $300 million in development and commercial milestones related to chronic obstructive pulmonary disease (COPD) product EP-101. Elevation is...
00:19 , Aug 31, 2012 |  BC Extra  |  Company News

Sunovion to acquire Elevation

The Sunovion Pharmaceuticals Inc. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) will acquire Elevation Pharmaceuticals Inc. (San Diego, Calif.) for $100 million up front and up to $300 million in development and commercial...
07:00 , Mar 31, 2008 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coveragec Opinion Wk chg 3/28 cls Antares (AMEX:AIS) Punk Mathew Kaplan Price target Buy 4% $0.95 Kaplan lowered his target to $2 from $3. He expects the potential...
08:00 , Jan 7, 2008 |  BioCentury  |  Finance

Post-launch report

Post-launch report Company Product Indication 2006 approval Sales through Sep 30 (A) Amgen (NASDAQ:AMGN) Vectibix panitumumab Metastatic colorectal cancer U.S. $137.0 Amylin (NASDAQ:AMLN)/ Eli Lilly (NYSE:LLY) Byetta exenatide Type II diabetes where metformin and/or...
08:00 , Nov 12, 2007 |  BC Week In Review  |  Clinical News

Brovana arformoterol tartrate regulatory update

The Centers for Medicare & Medicaid Services (CMS) assigned a product-specific billing code under the Medicare Part B benefit for Brovana arformoterol tartrate for use twice daily as long-term maintenance treatment for bronchoconstriction in patients...
07:00 , Oct 29, 2007 |  BC Week In Review  |  Clinical News

Brovana arformoterol tartrate: Phase II data

In an open-label Phase II trial in 39 patients, 15 µg of Brovana showed improvements in FEV1 that were similar to racemic formoterol. Data were presented at the American College of Chest Physicians meeting in...
07:00 , Oct 29, 2007 |  BC Week In Review  |  Clinical News

Brovana arformoterol tartrate pulmonary data

In a 4-week, double-blind study in 215 patients, Brovana did not prolong the QTc interval. Patients received twice-daily doses of 5, 10 or 25 µg Brovana or placebo for 2 weeks, followed by once-daily Brovana...
07:00 , Jun 25, 2007 |  BioCentury  |  Regulation

Shortness of breath

Sepracor Inc. may be about to lose more than a quarter of the market for its Xopenex levalbuterol as the result of a technicality in the Medicare law - and the Centers for Medicare &...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

Sepracor sales and marketing update

SEPR launched Brovana arformoterol tartrate inhalation solution, a twice-daily, long-term maintenance treatment for chronic obstructive pulmonary disease (COPD). The long-acting adrenergic receptor beta 2 agonist (LABA) bronchodilator is available in the U.S....